Cambridge Healthtech Institute’s 5th Annual

Immuno-Oncology Biomarkers

Patient Selection, Companion Diagnostics, and Immune Profiling

June 2-4, 2020


As pharmaceutical and biotechnology companies increase their investment in immuno-oncology programs to facilitate rapid development of novel immunotherapies, there is increasing pressure to discover and validate relevant biomarkers. Cambridge Healthtech Institute’s 5th annual Immuno-Oncology Biomarkers meeting will bring together biomarker experts from industry and academia to address rapid development of predictive and prognostic IO biomarkers, utility of these biomarkers in clinical trials, and their potential as companion diagnostics. 

IO BIOMARKERS FOR PATIENT SELECTION AND CLINICAL TRIALS

Clinical Trial Biomarkers
Jennifer Mataraza, PhD, Head, Translational Immuno-Oncology, Novartis Institutes for BioMedical Research

Deep Proteome-Based Theranostics in Immuno-Oncology
Michael H. A. Roehrl, MD, PhD, Director, Precision Pathology Center, Memorial Sloan Kettering Cancer Center; Associate Professor, Pathology and Laboratory Medicine, Weill Cornell Medicine

Biomarkers for Cancer Immunotherapy and Cellular Therapy Selection and Treatment Monitoring
Glen J. Weiss, MD, MBA, Senior Medical Director, Unum Therapeutics

INTEGRATED IMMUNE PROFILING AND ASSAY DEVELOPMENT

Integrative Analyses of Environment, Microbiome, Immunity, and Tumor for Precision Oncology
Shuji Ogino, MD, PhD, MS, Professor of Pathology, Brigham & Women’s Hospital, Harvard Medical School; Professor, Epidemiology, Harvard T.H. Chan School of Public Health; Chief of Molecular Pathological Epidemiology (MPE) Program, Brigham & Women's Hospital; Associate Member, Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard

How to “Read” Immune Responses with Exosomes and Other EVs
Jennifer C. Jones, MD, PhD, Investigator, Laboratory of Pathology, Head, Translational Nanobiology Section, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH)

Maximizing the Return on Clinical Samples: Considerations for IO Discovery Biomarker Analysis
Amber Donahue, PhD, Senior Manager, Biomarker Clinical Assay Lead, Oncology Clinical Assay Group, Pfizer

Immune Profiling
Veena Kandaswamy, PhD, Immuno-Oncology Biomarkers, Eli Lilly

BIOMARKERS OF RESPONSE AND RESISTANCE

PD-L1 Immunohistochemistry (IHC) as a Predictive Marker for the PD-1/PD-L1 Axis Blockade
Mari Mino-Kenudson, MD, Professor, Pathology, Harvard Medical School

Fatty Acid Oxidation is a Biomarker for Breast Cancer Chemo-Resistance and CD8 T Cell Suppression
Hua Eleanor Yu, PhD, Billy and Audrey Wilder Endowed Professor, Co-Leader, Cancer Immunotherapeutics Program, City of Hope Comprehensive Cancer Center

PROFILING THE TUMOR MICROENVIRONMENT

The Tumor Immune Microenvironment of Pre-Malignant Lesion in the Pancreas
Elizabeth Thompson, MD, PhD, Assistant Professor, Pathology and Oncology, The Johns Hopkins Hospital

Multiplex Immunofluorescence Tyramide Signal Amplification and Multispectral Imaging Assay to Support Translational Oncology Studies
Edwin Roger Parra Cuentas, MD, PhD, Assistant Professor, Translational Molecular Pathology, Director of the Multiplex Immunofluorescence and Image Analysis Laboratory, MD Anderson Cancer Center

Talk Title to be Announced
Dirk Brockstedt, PhD, CSO, RAPT Therapeutics

Talk Title to be Announced
Vanessa Tumilasci, PhD, Commercial Director, Trans-Hit Bio